Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: SNTI

Senti Biosciences, Inc.

Healthcare | Biotechnology

No licensed closing price on file for SNTI. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Senti Biosciences, Inc. (NASDAQ: SNTI) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 02:39 UTC.

What Senti Biosciences, Inc. does

Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies using proprietary gene circuit platform technologies for patients with incurable diseases. The company has built a synthetic biology platform designed to program next-generation cell and gene therapies with gene circuits that enable cells to sense inputs, compute decisions, and respond to their cellular environments.

Summarized from Senti Biosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-1,099.27%

Revenue, margins & earnings

FY2021: net loss $55M on revenue $3M$3MFY2021FY2022: net loss $58M on revenue $4M$4MFY2022FY2023: net loss $71M on revenue $3M$3MFY2023FY2025: net loss $61M on revenue $22,000$22,000FY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-03-11
Most recent filed transactions — March 2026:
  • 2026-03-11CEOTax withholding-80,666—
  • 2026-03-11Pres. & Chief Med. & Dev. Off.Tax withholding-10,757—
  • 2026-02-03CEOTax withholding-4,191—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →
No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does Senti Biosciences, Inc. do?

Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies using proprietary gene circuit platform technologies for patients with incurable diseases.

When did SNTI last file with the SEC?

Senti Biosciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-26. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:39 UTC. This page is also available as JSON at /api/data?ticker=SNTI and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SNTI and 5,000+ tickers.

Create a free account — keep SNTI
For your agent
GET /api/data?ticker=SNTI

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt